CT45A1 acts as a new proto-oncogene to trigger tumorigenesis and cancer metastasis

Cell Death and Disease

Volumn 5, Issue 6, 2014, Pages

  Shang, B ^a   Gao, A ^a   Pan, Y ^a   Zhang, G ^a   Tu, J ^b   Zhou, Y ^a   Yang, P ^a   Cao, Z ^a   Wei, Q ^a   Ding, Y ^a   Zhang, J ^a   Zhao, Y ^a   Zhou, Q ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTING ANTIGEN 45; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CREB1 PROTEIN, HUMAN; CT45A1 PROTEIN, HUMAN; ONCOPROTEIN;

ARTICLE; BREAST CANCER CELL LINE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; UP-REGULATION;

EID: 84903775552     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.244     Document Type: Article

References (47)

1. Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M, Stassi G et al. Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol 2013; 23: 522-532.
2. Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol 2011; 5: 164-182.
3. Whitehurst AW. Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol 2013; 54: 251-272.
4. der Bruggen Pv, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
5. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176: 1453-1457.
6. Chen YT, Boyer AD, Viars CS, Tsang S, Old LJ, Arden KC et al. Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogenet Cell Genet 1997; 79: 237-240.
7. John T, Starmans MH, Chen YT, Russell PA, Barnett SA, White SC et al. The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. PLoS One 2013; 8: e67876.
8. Ogata K, Aihara R, Mochiki E, Ogawa A, Yanai M, Toyomasu Y et al. Clinical significance of melanoma antigen-encoding gene-1 (MAGE-1) expression and its correlation with poor prognosis in differentiated advanced gastric cancer. Ann Surg Oncol 2011; 18: 1195-1203.
9. Chen Z, Li M, Yuan Y, Wang Q, Yan L, Gu J et al. Cancer/testis antigens and clinical risk factors for liver metastasis of colorectal cancer: a predictive panel. Dis Colon Rectum 2010; 53: 31-38.
10. Pandey A, Kurup A, Shrivastava A, Radhi S, Nguyen DD, Arentz C et al. Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol 2012; 31: 302-320.
11. Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B et al. Cancer/testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med 2011; 9: 153.
12. von BL, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T et al. MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer. PLoS One 2011; 6: e21366.
13. Ayyoub M, Taub RN, Keohan ML, Hesdorffer M, Metthez G, Memeo L et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004; 4: 7.
14. Inaoka RJ, Jungbluth AA, Gnjatic S, Ritter E, Hanson NC, Frosina D et al. Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients. Cancer Immunol Immunother 2012; 61: 2207-2214.
15. Dobrynin P, Matyunina E, Malov SV, Kozlov AP. The novelty of human cancer/testis antigen encoding genes in evolution. Int J Genomics 2013; 2013: 105108.
16. Chen YT, Hsu M, Lee P, Shin SJ, Mhawech-Fauceglia P et al. Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. Int J Cancer 2009; 124: 2893-2898.
17. Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One 2011; 6: e17876.
18. Zhou X, Yang F, Zhang T, Zhuang R, Sun Y, Fang L et al. Heterogeneous expression of CT10, CT45 and GAGE7 antigens and their prognostic significance in human breast carcinoma. Jpn J Clin Oncol 2013; 43: 243-250.
19. Andrade VC, Vettore AL, Regis Silva MR, Felix RS, Almeida MS, de Carvalho F et al. Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma. Exp Hematol 2009; 37: 446-449.
20. Cerveira N, Meyer C, Santos J, Torres L, Lisboa S, Pinheiro M et al. A novel spliced fusion of MLL with CT45A2 in a pediatric biphenotypic acute leukemia. BMC Cancer 2010; 10: 518.
21. Heidebrecht HJ, Claviez A, Kruse ML, Pollmann M, Buck F, Harder S et al. Characterization and expression of CT45 in Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 4804-4811.
22. Chen YT, Chadburn A, Lee P, Hsu M, Ritter E, Chiu A et al. Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proc Natl Acad Sci USA 2010; 107: 3093-3098.
23. Inaoka RJ, Jungbluth AA, Baiocchi OC, Assis MC, Hanson NC, Frosina D et al. An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients. BMC Cancer 2011; 11: 416.
24. Koop A, Sellami N, Adam-Klages S, Lettau M, Kabelitz D, Janssen O et al. Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. Cell Commun Signal 2013; 11: 16.
25. Nairismagi ML, Vislovukh A, Meng Q, Kratassiouk G, Beldiman C, Petretich M et al. Translational control of TWIST1 expression in MCF-10A cell lines recapitulating breast cancer progression. Oncogene 2012; 31: 4960-4966.
26. Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato Y, Aziz K et al. Required for Twist1-induced prostate cancer metastasis. Mol Cancer Res 2013; 11: 1387-1400.
27. Isfoss BL, Holmqvist B, Jernstrom H, Alm P, Olsson H. Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules. BMC Clin Pathol 2013; 13: 15.
28. Charafe-Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Finetti P et al. ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res 2013; 73: 7290-7300.
29. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005; 13: 205-220.
30. Regan JL, Kendrick H, Magnay FA, Vafaizadeh V, Groner B, Smalley MJ. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer. Oncogene 2012; 31: 869-883.
31. Germano S, Kennedy S, Rani S, Gleeson G, Clynes M, Doolan P et al. MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. Int J Cancer 2012; 130: 1991-2002.
32. Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat Rev Cancer 2010; 10: 361-371.
33. Fischbach NA, Rozenfeld S, Shen W, Fong S, Chrobak D, Ginzinger D et al. HOXB6 overexpression in murine bone marrow immortalizes a myelomonocytic precursor in vitro and causes hematopoietic stem cell expansion and acute myeloid leukemia in vivo. Blood 2005; 105: 1456-1466.
34. Cantile M, Franco R, Tschan A, Baumhoer D, Zlobec I, Schiavo G et al. HOX D13 expression across 79 tumor tissue types. Int J Cancer 2009; 125: 1532-1541.
35. Whelan JT, Hollis SE, Cha DS, Asch AS, Lee MH. Post-transcriptional regulation of the Ras-ERK/MAPK signaling pathway. J Cell Physiol 2012; 227: 1235-1241.
36. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012; 16(Suppl 2): S17-S27.
37. Siu YT, Jin DY. CREB-a real culprit in oncogenesis. FEBS J 2007; 274: 3224-3232.
38. Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M et al. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 2005; 7: 1001-1010.
39. Gill RB, Day A, Barstow A, Liu H, Zaman G, Dhoot GK et al. Sulf2 gene is alternatively spliced in mammalian developing and tumour tissues with functional implications. Biochem Biophys Res Commun 2011; 414: 468-473.
40. Bret C, Moreaux J, Schved JF, Hose D, Klein B. SULFs in human neoplasia: implication as progression and prognosis factors. J Transl Med 2011; 9: 40.
41. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
42. Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001; 345: 833-835.
43. Furusato B, Mohamed A, Uhlen M, Rhim JS. CXCR4 and cancer. Pathol Int 2010; 60: 497-505.
44. Xu TP, Shen H, Liu LX, Shu YQ. The impact of chemokine receptor CXCR4 on breast cancer prognosis: a meta-analysis. Cancer Epidemiol 2013; 37: 725-731.
45. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761-1767.
46. Mukherjee D, Zhao J. The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res 2013; 3: 46-57.
47. Yamada R, Takahashi A, Torigoe T, Morita R, Tamura Y, Tsukahara T et al. Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene. Tissue Antigens 2013; 81: 428-434.